

	Population							
	Original		Matched		ATT-weighted		ATE-weighted	
	Untreated	Treated	Untreated	Treated	Untreated	Treated	Untreated	Treated
Number of patients, N (%)	5,045 (50.5)	4,955 (49.6)	4,950 (50.0)	4,950 (50.0)	5,001 (50.2)	4,955 (49.8)	10,046 (50.1)	9,997 (49.9)
Male, N (%)	1,451 (28.8)	3,493 (70.5)	3,477 (70.2)	3,488 (70.5)	3,538 (70.8)	3,493 (70.5)	4,989 (49.7)	4,940 (49.4)
Risk score, N (%)								
0	2,543 (50.4)	2,506 (50.6)	2,482 (50.1)	2,502 (50.5)	2,529 (50.6)	2,506 (50.6)	5,072 (50.5)	5,047 (50.5)
1	2,502 (49.6)	2,449 (49.4)	2,468 (49.9)	2,448 (49.5)	2,472 (49.4)	2,449 (49.4)	4,974 (49.5)	4,951 (49.5)
Comorbidity score, N (%)								
0	1,381 (27.4)	1,072 (21.6)	1,066 (21.5)	1,072 (21.7)	1,062 (21.2)	1,072 (21.6)	2,443 (24.3)	2,444 (24.4)
1-2	2,512 (49.8)	2,516 (50.8)	2,487 (50.2)	2,513 (50.8)	2,524 (50.5)	2,516 (50.8)	5,036 (50.1)	5,032 (50.3)
3+	1,152 (22.8)	1,367 (27.6)	1,397 (28.2)	1,365 (27.6)	1,414 (28.3)	1,367 (27.6)	2,566 (25.5)	2,521 (25.2)
Age, median (Q1-Q3)	48.2 (41.3;54.8)	51.9 (45.1;58.3)	51.8 (45.9;58.1)	51.9 (45.1;58.3)	52.0 (45.4;58.9)	51.9 (45.1;58.3)	50.2 (43.1;56.9)	50.1 (43.1;56.6)